

GRI Index for Biogen's 2017 Corporate Citizenship Report

General Standard Disclosures

Strategy and Analysis

G4-1	CEO Statement	CEO Note
G4-2	Description of key impacts, risks and opportunities.	A description of our key risks can be found in Item 1A., Risk Factors, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (" 2017 Form 10-K "), pages 33-46.

Organizational Profile

G4-3	Name of reporting organization	Biogen Inc.
G4-4	Products	Biogen's marketed products include TECFIDERA®, AVONEX®, PLEGRIDY®, TYSABRI® and FAMPYRA™ for the treatment of multiple sclerosis (MS); SPINRAZA® for the treatment of spinal muscular atrophy (SMA); and FUMADERM™ for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN® for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA® for the treatment of CLL and follicular lymphoma, OCREVUS® for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc., a wholly-owned member of the Roche Group. In March 2018 we and AbbVie Inc. announced the voluntary worldwide withdrawal of ZINBRYTA® for relapsing MS.
G4-5	HQ location	Biogen's world headquarters: Cambridge, Mass., United States. International headquarters: Zug, Switzerland
G4-6	Countries of operation	Biogen operates in The Americas, Europe, Asia and Australia. A more detailed breakdown is available on our website.
G4-7	Nature of ownership and legal form	Biogen (BIIB) is publicly traded on the Nasdaq Stock Exchange.
G4-8	Markets served	A breakdown of our products and markets served is detailed in Item 1., Business, in our 2017 Form 10-K , pages 9-12.
G4-9	Report the scale of the organization, including:	
	<ul style="list-style-type: none"> Total number of employees 	As of December 31, 2017, Biogen had approximately 7,300 employees worldwide.
	<ul style="list-style-type: none"> Total number of operations 	A summary of Biogen's owned and leased properties as of December 31, 2017, is included in Item 2., Properties, in our 2017 Form 10-K , pages 46-47.
	<ul style="list-style-type: none"> Net sales (for private sector organizations) or net revenues (for public sector organizations) 	Selected financial information can be found in Item 6., Selected Financial Data, in our 2017 Form 10-K , pages 50-52.
	<ul style="list-style-type: none"> Total capitalization broken down in terms of debt and equity (for private sector organization) 	
	<ul style="list-style-type: none"> Quantity of products or services provided 	Quantities of products provided, by revenues, can be found in Item 1., Business, in our 2017 Form 10-K , page 9.

G4-10	<ul style="list-style-type: none"> Report the total number of employees by employment contract and gender. Report the total number of permanent employees by employment type and gender. Report the total workforce by region and gender. Report any significant variations in employment numbers. 	<p>As of December 31, 2017, Biogen employed approximately 7,300 full-time permanent employees, most of whom are highly skilled. The vast majority of work is performed by company employees, not contract workers.</p> <p>There were not significant variations in employment numbers compared to 2016. Nearly half of Biogen’s employees are women.</p>
G4-11	Report the percentage of employees covered by collective bargaining agreements.	Approximately 5.8 percent of our employees are under a collective bargaining agreement. All of these employees work in our Hillerød, Denmark, manufacturing facility.
G4-12	Describe the organization’s supply chain.	A description of our supply chain can be found in Item 1., Business, in our 2017 Form 10-K , page 28.
G4-13	Report any significant changes during the reporting period regarding the organization’s size, structure, ownership or its supply chain.	<p>During 2017 we had a number of key developments affecting our business including an updated strategic framework to optimize the value of our MS business while investing for the future across our core growth areas of MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders and neuromuscular diseases, including SMA and amyotrophic lateral sclerosis (ALS). In 2017 we also approved a corporate restructuring program intended to streamline our operations and reallocate resources. Other significant changes took place in 2017, such as the spin-off of our hemophilia business. More details are available in Item 1., Business, in our 2017 Form 10-K, pages 2-4.</p>
G4-14	Report whether and how the precautionary approach or principle is addressed by the organization.	Biogen applies the precautionary approach by achieving carbon neutrality, ensuring the safety of patients, and performing detailed risk analyses related to our operations.
G4-15	List externally developed economic, environmental and social charters, principles or other initiatives to which the organization subscribes or which it endorses.	Biogen has aligned its strategy with six of the Sustainable Development Goals. More details are available in the GRI Report section.
G4-16	<p>List memberships of associations (such as industry associations) and national or international advocacy organizations in which the organization:</p> <ul style="list-style-type: none"> Holds a position on the governance body Participates in projects or committees Provides substantive funding beyond routine membership due Views membership as strategic <p>This refers primarily to memberships maintained at the organizational level.</p>	<ul style="list-style-type: none"> Biogen chairs the green chemistry working group of the International Consortium of Innovation & Quality in Pharmaceutical Development (the IQ Consortium) and is a member of the American Chemical Society (ACS) Green Chemistry Roundtable. More details are available in the Green Chemistry section. Biogen is also a member of RE100, a collaborative, global initiative uniting more than 100 influential businesses committed to 100% renewable electricity. Biogen actively participates in the Pharmaceutical Product Stewardship Work Group (PPSWG), a U.S. membership association of major manufacturers of prescription and over-the-counter medicines, and the Sharps Working Group, which focuses on establishing sound sharps safety and collection and disposal policy, educating patients about their options and coordinating pharmaceutical industry compliance in the U.S. Biogen is an active member of the Pharmaceutical Supply Chain Initiative (PSCI), an organization made up of 24 leading global pharmaceutical companies that focuses on increasing the capabilities and responsibility of our supply chains.

Identified Material Aspects and Boundaries

G4-17	List all entities included in the organization's consolidated financial statements or equivalent documents. Report whether any entity included in the organization's consolidated financial statements or equivalent documents is not covered by the report.	All major entities are included in the boundaries of this report. See the 2017 Form 10-K .
G4-18	Explain the process for defining the report content and the Aspect Boundaries. Explain how the organization has implemented the Reporting Principles for Defining Report Content.	GRI Materiality Assessment
G4-19	List all the material Aspects identified in the process for defining report content.	GRI Index, see Specific Standard Disclosures
G4-20	For each material Aspect, report the Aspect Boundary within the organization.	GRI Index, see Specific Standard Disclosures
G4-21	For each material Aspect, report the Aspect Boundary outside the organization.	GRI Index, see Specific Standard Disclosures
G4-22	Report the effect of any restatements of information provided in previous reports, and the reasons for such restatements.	No restatements were made.
G4-23	Report significant changes from previous reporting periods in the Scope and Aspect Boundaries.	No significant changes from the previous reporting period.

Stakeholder Engagement

G4-24	Provide a list of stakeholder groups engaged by the organization.	GRI Materiality Assessment
G4-25	Report the basis for identification and selection of stakeholders with whom to engage.	GRI Materiality Assessment
G4-26	Report the organization's approach to stakeholder engagement.	GRI Materiality Assessment
G4-27	Report key topics and concerns that have been raised through stakeholder engagement, and how the organization has responded to those key topics and concerns, including through its reporting.	GRI Materiality Assessment

Report Profile

G4-28	Reporting period (such as fiscal or calendar year) for information provided.	Data covers fiscal year 2017; ending December 31, 2017. Some activities from 2018 are also included.
G4-29	Date of most recent previous report (if any).	Fiscal year 2016

G4-30	Reporting cycle (such as annual, biennial).	Annual
G4-31	Provide the contact point for questions regarding the report or its contents.	impact@biogen.com
G4-32	Report the “in accordance” option the organization has chosen. Report the GRI Content Index for the chosen option. Report the reference to the External Assurance Report, if the report has been externally assured.	GRI G4 in accordance at the Core level External assurance statement can be found on the 2017 Corporate Citizenship Report website.
G4-33	Report the organization’s policy and current practice with regard to seeking external assurance for the report.	Biogen seeks external assurance for some of its environmental data, as well as its workplace safety and diversity data.

Governance

G4-34	Report the governance structure of the organization, including committees of the highest governance body. Identify any committees responsible for decision-making on economic, environmental and social impacts.	Details on Biogen’s Board of Directors and Corporate Governance and Executive Leadership <ul style="list-style-type: none"> • The Risk Committee of the Board of Directors oversees the management of material risks facing the Company, including topics such as information technology, cybersecurity, environmental, health and sustainability and other material risks not allocated to our Board of Directors or another committee. • At the executive leadership level, our corporate citizenship strategy is overseen by the Global Impact Executive Council, which includes members of Biogen’s senior leadership team. • In 2017, Biogen also added its first Stakeholder Advisory Council, made up of external stakeholders who help to review trends, benchmark our peers and recommend improvements to goals and initiatives.
-------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ethics and Integrity

G4-56	Describe the organization’s values, principles, standards and norms of behavior such as codes of conduct and codes of ethics.	The Values in Action: Code of Business Conduct
-------	-------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------

Specific Standard Disclosures

Material Aspects	G4 Categories and Material Aspects	Specific Standard Disclosures	Stakeholders Impacted or Involved	Relevance and Approach	Report Link
Patient Health Outcomes <ul style="list-style-type: none"> Patient engagement 	Economic Indirect Economic Impact	G4-EC8 Significant indirect economic impacts, including the extent of impacts.	<ul style="list-style-type: none"> Patients Caregivers Healthcare providers & systems Patient advocacy groups Governments Insurers & payers 	Our therapies are intended to treat specific neurological and neurodegenerative diseases that can be debilitating to patients, especially if their conditions go untreated. A lack of treatment can also have a significant economic impact on the healthcare system. Engaging and educating patients and caregivers about treatment options, as well as opening doors to patient support resources, are critically important measures in improving health outcomes.	Our Commitments to Patient Communities Patient Health Outcomes
Access to Treatments <ul style="list-style-type: none"> Clinical trials Patient assistance Biosimilars Pricing 	Economic Indirect Economic Impact	G4-EC8 Significant indirect economic impacts, including the extent of impacts.	<ul style="list-style-type: none"> Patients Caregivers Healthcare providers & systems Patient advocacy groups Governments Insurers & payers 	An enormous investment of time and money is required to discover and develop new therapies intended to treat complex neurological and neurodegenerative conditions. The high costs of these medications are reflective of the investment made and the value these therapies provide to patients and the healthcare system. But drug pricing should not be a barrier to access. We have established pricing principles and assistance programs to help patients who may benefit from access our treatments, including outreach to underserved patients. Clinical trials provide another avenue for patients to access potential options for treatment. And investing in the development of biosimilar therapies is yet another opportunity to deliver viable therapies at more affordable costs.	Our Commitments to Patient Communities Access to Treatments
R&D and Pipeline <ul style="list-style-type: none"> Collaborations 	Economic Indirect Economic Impact	G4-EC8 Significant indirect economic impacts, including the extent of impacts.	<ul style="list-style-type: none"> Patients Healthcare providers & systems Patient advocacy groups Governments Insurers & payers Investors Business partners 	While tremendous advances have been made in the treatment of neurological and neurodegenerative diseases, unmet medical needs remain. Continual investment is needed to research, develop and maintain a robust pipeline of promising new therapies that have the potential to improve patient outcomes. Our R&D efforts are often done in collaboration with other biopharmaceutical entities, enabling us to combine strengths and competencies to achieve mutual goals.	Our Business R&D and Pipeline Our Guiding Principles Research Collaborations

<p>Information Security</p> <ul style="list-style-type: none"> • Patient privacy • Data protection 	<p>Product Responsibility</p> <p>Customer Privacy</p>	<p>G4-PR8 Total number of substantiated complaints regarding breaches of customer privacy and losses of customer data.</p>	<ul style="list-style-type: none"> • Patients • Healthcare providers & systems • Employees 	<p>We collect information on patients who participate in our clinical trials and those whom we engage through various patient programs. We uphold the law to protect their privacy and safeguard their personal health information by preventing unauthorized access to – or sharing of their data. The same is true of our employees. Having a privacy policy and adhering to it is essential. And given today’s risks of information breaches, it’s critically important to have sound cybersecurity measures in place.</p>	<p>Our Guiding Principles</p> <p>Global Privacy Program</p> <p>Clinical Trial Transparency and Data Sharing</p>
<p>Product Stewardship</p> <ul style="list-style-type: none"> • Product quality & safety • Counterfeit protection • Pharmaceuticals in the Environment (PiE) 	<p>Product Responsibility</p> <p>Customer Health & Safety</p> <p>Product and Service Labeling</p> <p>Environmental</p> <p>Products and Services</p>	<p>G4-PR1 Percentage of significant product and service categories for which health and safety impacts are assessed for improvement.</p> <p>G4-PR3 Type of product and service information required by the organization’s procedures for products and service information and labeling, and percentage of significant product and service categories subject to such information requirements.</p> <p>G4-EN28 Percentage of products sold and their packaging materials that are reclaimed by category.</p>	<ul style="list-style-type: none"> • Patients • Healthcare providers & systems • Governments • NGOs • Industry groups 	<p>We consider product stewardship to be fundamental to everything we do. It encompasses the quality and safety of our products, and extends to the prevention of counterfeits, and the impact of chemistry on the environment and in the manufacturing of our products. We comply with all applicable regulations in the disposal of our products and supplies, and use state-of-the-art technology to safeguard the authenticity and security of our products.</p>	<p>Our Guiding Principles</p> <p>Product Stewardship</p>

<p>Green Chemistry</p>	<p>Environmental</p> <p>Products and Services</p>	<p>G4-EN27 Extent of impact mitigation of environmental impacts of products and services. Extent of impact mitigation of environmental impacts of products and services.</p>	<ul style="list-style-type: none"> • Patients • Healthcare providers & systems • Governments • NGOs • Industry groups 	<p>There are continual innovations being made in the design, development and production of biologics. This includes the growing emergence of green chemistry, an approach aimed at reducing or eliminating the use of toxic chemicals and generation of hazardous materials. There are other environmental benefits that can result from green chemistry - such as more efficient processes, and/or reduced energy and/or water use.</p>	<p>Our Environment</p> <p>Green Chemistry</p>
<p>Responsible & Sustainable Supply Chain</p> <ul style="list-style-type: none"> • Environmental, Social & Governance (ESG) risk assessments 	<p>Environmental</p> <p>Supplier Environmental Assessment</p> <p>Human Rights Supplier Human Rights Assessment</p>	<p>G4-EN32 Percentage of new suppliers that were screened using environmental criteria.</p> <p>G4-EN33 Significant actual and potential negative environmental impacts in the supply chain and actions taken.</p> <p>G4-HR10 Percentage of new suppliers that were screened using human rights criteria.</p> <p>G4-HR11 Significant actual and potential negative impacts on human rights in the supply chain and actions taken.</p>	<ul style="list-style-type: none"> • Suppliers • Customers • Governments • NGOs • Local communities 	<p>Our stakeholders expect that we understand the environmental, social and governance (ESG)-related risks and impacts across our supply chain, and that we take steps to manage these risks and impacts. Biogen has developed evaluation processes to fulfill this expectation with the objective of identifying any potential at-risk suppliers that could warrant further evaluation. Overall, Biogen has a low ESG-related risk profile due to the current geographical spread of suppliers and the nature of the goods and services purchased.</p> <p>Our evaluation processes include:</p> <ul style="list-style-type: none"> • ESG risk screens for critical supplier sites • Water risk basin-level screen for a subset of critical supplier sites • Human rights country-level risk screen against our entire procurement spend • Monitoring compliance with new requirements around the world (e.g. human trafficking legislation) <p>Critical suppliers are defined as approved Good Manufacturing Practice (GMP) supplier sites that supply products and services directly related to the safety and integrity of our products. High-volume and any non-substitutable suppliers are often GMP suppliers.</p> <p>ESG Risk Screen: In 2017, we evaluated 942 critical suppliers sites (684 Tier I supplier sites representing 57 percent of total procurement spend and 260 Tier II supplier sites). This evaluation assesses each supplier against five factors – criticality of the service or good being supplied (30 percent); the level of financial spend (35 percent); the social risk profile (11 percent); the environmental risk profile (12 percent); and the governance risk profile,</p>	<p>Our Guiding Principles</p> <p>Supply Chain Responsibility</p>

including potential for corruption (12 percent). Six Tier I supplier sites and zero Tier II supplier sites were screened as potentially higher risk requiring further internal evaluation of the supplier's practices and service/goods provided. The conclusion of the internal evaluation deemed zero of the six supplier sites to present a high risk to Biogen operations.

Water Risk Screen: In 2017, we evaluated 169 of the most critical GMP supplier sites using the Water Risk Filter Tool developed by WWF and DEG. Two supplier sites were screened as potentially higher risk requiring further internal evaluation. The conclusion of the internal evaluation deemed zero of the two supplier sites to present a high risk to Biogen operations.

Human Rights Risk Screen: In 2017, we evaluated nearly 100 percent of procurement spend against the country-level risk profiles developed by the U.S. State Department's *2017 Trafficking in Persons Report*. Our procurement system registered a total of 12,670 unique supplier country-level locations (i.e., Biogen may purchase goods or services from a single supplier in multiple countries, where each is included in the screen) with aggregate purchases equal to or greater than \$1,000:

- 11,925 unique supplier locations (96 percent of spend) were in Tier 1 countries.
- 601 unique supplier locations (4 percent of spend) were in Tier 2 countries.
- 124 unique supplier locations (<0.1 percent of spend) were in Tier 2 Watch List countries.
- 20 unique supplier locations (<0.1 percent of spend) were in Tier 3 countries.

The supplier locations in Tier 2 Watch and Tier 3 countries were further evaluated in a similar manner as described in the ESG risk screen. The evaluation determined zero of these supplier locations to be high risk.

To support the continual improvement of Biogen's ability to assess risk within its supply chain, two targets have been set:

- Expand ESG risk screening of Tier I suppliers to 75 percent of spend by 2020.
- Expand ESG risk screening of Tier II supplier sites to 500 sites by 2020.

<p>Responsible & Sustainable Supply Chain</p> <ul style="list-style-type: none"> Supplier diversity 	<p>Economic</p> <p>Procurement Practices</p>	<p>G4-EC9 Proportion of spending on local suppliers at significant locations of operation.</p>	<ul style="list-style-type: none"> Suppliers Customers Governments NGOs Local communities 	<p>Our supplier diversity initiatives are intended to create a diverse and inclusive supplier base so that suppliers, regardless of size and scale of their enterprises, have opportunities to compete for our business. We consider our supplier diversity program a fundamental component of fostering a responsible and sustainable supply chain.</p>	<p>Our Guiding Principles</p> <p>Supply Chain Responsibility</p>
<p>Climate Change</p> <ul style="list-style-type: none"> Energy use and renewables GHG emissions Supplier engagement 	<p>Environmental</p> <p>Energy Emissions Supplier Environmental Assessment</p>	<p>G4-EN3 Energy consumption within the organization.</p> <p>G4-EN4 Energy consumption outside of the organization.</p> <p>G4-EN3 Energy intensity.</p> <p>G4-EN15 Direct GHG emissions (Scope 1).</p> <p>G4-EN16 Energy indirect GHG emissions (Scope 2).</p> <p>G4-EN17 Other indirect GHG emissions (Scope 3).</p> <p>G4-EN19 Reduction of greenhouse gas (GHG) emissions.</p> <p>G4-EN32 Percentage of new suppliers that were screened using environmental criteria.</p>	<ul style="list-style-type: none"> Governments NGOs Suppliers Communities Patients 	<p>Climate change is a global concern that has potential implications on human health and the long-term sustainability of our environment. Recognizing that every entity has a carbon footprint, we have been working to reduce our impact through energy efficiency measures and investments in renewables aimed at maintaining our carbon neutrality. We have also engaged our key suppliers and encouraged them to measure and report their carbon emissions.</p>	<p>Our Environment</p> <p>Climate and Carbon Strategy</p> <p>Our Guiding Principles</p> <p>Climate Change Position</p>

<p>Water & Wastewater (Operations)</p> <ul style="list-style-type: none"> Water use Wastewater 	<p>Environmental Water Effluents and Waste</p>	<p>G4-EN8 Total water withdrawal by source.</p> <p>G4-EN8 Percentage and total volume of water recycled and reused.</p> <p>G4-EN22 Total water discharge by quality and destination.</p>	<ul style="list-style-type: none"> Governments NGOs Suppliers Communities 	<p>In certain parts of the world, water resources are constrained and/or lacking. Water pollution is also of great concern. Yet water is a critical resource – used in our products and for our manufacturing processes. We are taking great measures to reduce our water use, reuse/recycle the water we use within our manufacturing processes and ensure the water that is returned to the environment is clean and as free of pharmaceutical ingredients as possible.</p>	<p>Our Environment</p> <p>Water</p>
<p>Waste</p>	<p>Environ-mental Effluents and Waste</p>	<p>G4-EN23 Total weight of waste by type and disposal method.</p> <p>G4-EN23 Weight of transported, imported, exported, or treated wasted deemed hazardous, and percentage of transported waste shipped internationally.</p>	<ul style="list-style-type: none"> Governments NGOs Suppliers Communities 	<p>Waste is a byproduct resulting from the manufacturing process. But much can be – and should be – done to reduce waste streams and minimize the amount of waste to landfill. Biogen has a zero-to-landfill goal, which we have met and maintained.</p> <p>Hazardous waste, another byproduct of our manufacturing operations, needs to be properly handled and managed. This is one of our priorities.</p>	<p>Our Environment</p> <p>Goals and Performance</p>
<p>Recruitment & Retention</p> <ul style="list-style-type: none"> Employee engagement and retention 	<p>Labor Practices Employment</p>	<p>G4-LA1 Total number of employees.</p>	<ul style="list-style-type: none"> Employees Prospective employees Communities Investors 	<p>The biotech industry relies on a talent pool of highly trained and specialized individuals. To attract and retain the best employees, it is essential to have a rewarding and engaging workplace environment that enables employees to grow their careers and thrive while making a meaningful difference in improving patient lives. This is our focus at Biogen – for all of the approximately 7,300 people we employed as of December 31, 2017.</p>	<p>Our Community</p> <p>Workplace Community</p> <p>Talent Acquisition & Retention</p>

Workplace Health & Safety	Labor Practices Occupation-al Health & Safety	G4-LA6 Type of injury and rates of injury, occupational diseases, lost days and absenteeism and total number of work-related fatalities, by region and by gender.	<ul style="list-style-type: none"> • Employees • Governments 	<p>In any manufacturing environment, worker safety issues are not uncommon. But injuries to workers can happen in any type of workplace– from an office environment to distribution operations. Safety practices must be continually taught and reinforced, and emerging risks must be identified early on and proactively managed. The priority at Biogen is to keep our people safe and dramatically reduce or eliminate the risk of injury.</p>	Our Community Workplace Health & Safety
Workplace Diversity & Inclusion	Labor Practices Diversity & Equal Opportunity	G4-LA12 Composition of governance bodies and breakdown of employees per employee category according to gender, age group, minority group membership and other indicators of diversity.	<ul style="list-style-type: none"> • Employees • Patients • Local communities • Governments 	<p>Patients come from all walks of life. To truly understand our patients’ perspectives and unique differences, we must have a workforce that is representative of the patients we serve. The same is true for the communities in which we operate – we must mirror our neighbors, suppliers and partners. In years past, the biotech industry has tended to be male-dominated, but in more recent years, a growing number of women have pursued careers in science. Biogen has made a point to be a place where women have opportunities to advance and assume leadership roles. As a result, we have succeeded at having nearly equal representation of women at Biogen.</p>	Our Community Diversity & Inclusion
Transparency & Disclosure <ul style="list-style-type: none"> • Clinical trails • Political activities & public policy 	Society Public Policy	G4-S06 Total value of political contributions by country and recipient/beneficiary .	<ul style="list-style-type: none"> • Governments • Investors • Patients • Healthcare providers & systems 	<p>There are several critical areas where the pharma & biotech industries have been pushed to be more transparent: on the outcomes of their clinical trials; pricing policies; and their political activities and contributions. We believe transparency is the mark of a responsible company, and have taken steps to increase our transparency in these areas in particular.</p>	Our Guiding Principles Transparency Reporting Clinical Trial Transparency and Data Sharing

Bioethics <ul style="list-style-type: none"> Animal welfare Responsible marketing and labeling 	Product Responsibility Marketing Communications	G4-PR7 Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion and sponsorship, by type of outcomes.	<ul style="list-style-type: none"> Patients Healthcare providers & systems Insurers & payers Governments NGOs 	As the field of biotechnology advances, there are social and ethical implications that must be considered and reconciled. This includes issues such as stem cell research, animal welfare and the marketing and communications about biotech therapies and medicines. Biogen has strong practices in place regarding these various issues and is continually monitoring for new and emerging issues that could potentially be in the spotlight in the future.	Our Guiding Principles Animal Welfare
Compliance	Society Compliance	G4-S08 Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with laws and regulations.	<ul style="list-style-type: none"> Governments Patients Healthcare providers & systems 	Regulatory compliance is a significant focus within the biotech industry, and one of the more complex aspects to operating our business. Biogen must be innovative to remain competitive, and at the same time, compliant with the laws, rules and guidance enforced by multiple agencies that may have differing regulatory goals. There were no significant instances of noncompliance in 2017.	Our Guiding Principles Comprehensive Compliance Program
Community Engagement	Economic Economic Performance	G4-EC1 Direct economic value generated and distributed.	<ul style="list-style-type: none"> Local communities Employees Patients 	Positive engagement with and support of local communities is critically important for any major business to maintain its license to operate and build good will with residents and municipalities. Employees are also eager to see their companies play a positive role in the communities in which they work and live. And just as important to employees, they want to take part in “giving back” to local organizations that serve to improve their communities. Biogen believes in being a good neighbor, serving its communities and providing opportunities for employees to participate as well. The Biogen Foundation is the giving arm of Biogen, making grants on behalf of the company to support science education in many forms. Our employees are often involved in raising awareness and funds for the nonprofit organizations serving the patient populations affected by the neurological and neurodegenerative diseases that Biogen treats through its therapies.	Our Community The Biogen Foundation Community Lab Community Engagement